Psychometric Validation of the Child Health Questionnaire (CHQ) in a Sample of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Measuring health-related quality of life (HRQL) in children with attention-deficit/hyperactivity disorder (ADHD) in clinical trials can complement efficacy measures, offering a complete picture of the impact of disease and treatment on overall well-being. The purpose of the current study was to psyc...

Full description

Saved in:
Bibliographic Details
Published in:Quality of life research 2005-04, Vol.14 (3), p.719-734
Main Authors: Anne M. Rentz, Louis S. Matza, Kristina Secnik, Andrine Swensen, Revicki, Dennis A.
Format: Article
Language:English
Subjects:
Adolescent
Atomoxetine Hydrochloride
Attention Deficit Disorder with Hyperactivity - drug therapy
Attention Deficit Disorder with Hyperactivity - psychology
Attention deficit hyperactivity disorder
Child
Child Behavior
Children & youth
Childrens health
Disorders
Emotions
Family
Female
Humans
Hyperactivity
Male
Mental health
Missing data
Parents
Propylamines - therapeutic use
Psychometrics
Quality of Life
Questionnaires
Sickness Impact Profile
Surveys and Questionnaires
Symptoms
Transponders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Measuring health-related quality of life (HRQL) in children with attention-deficit/hyperactivity disorder (ADHD) in clinical trials can complement efficacy measures, offering a complete picture of the impact of disease and treatment on overall well-being. The purpose of the current study was to psychometrically validate a multidimensional, generic HRQL instrument completed by parents of children with ADHD. A total of 921 children and adolescents with ADHD participated in a clinical study of atomoxetine. Subjects' parents completed the 50-item Child Health Questionnaire-Parent Version (CHQ-PF50) at baseline and week 10. ADHD symptoms and behavioral problems were assessed using parent and clinician rating scales. Internal consistency reliability at baseline was 0.88 for the CHQ-PF50 Psychosocial Summary Score, ranging from 0.53 to 0.91 for subscale scores. Construct validity was supported by statistically significant correlations between CHQ-PF50 psychosocial scores and parent and clinician symptom ratings. Several methods were used to determine clinically meaningful differences in patient outcomes: inter- and intra-patient mean CHQ-PF50 change scores were tested and standard error of measurement (SEM) and effect sizes were calculated. Study results indicate the CHQ-PF50 is reliable, valid, and responsive to change in ADHD symptoms, suggesting it may provide a means of assessing HRQL outcomes associated with treatments for ADHD.
ISSN:0962-9343
1573-2649
DOI:10.1007/s11136-004-0832-9